Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Advisory Panel To Evaluate Acetaminophen Pediatric Dosing

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA expects the meeting to focus on single ingredient products, especially for children younger than 2, and to consider adding a weight-based dosing regimen to the existing age-based dosing for children 2-12.

You may also be interested in...



OTC pediatric analgesic directions for infant dosing recommended by NDAC.

OTC PEDIATRIC ANALGESIC/ANTIPYRETIC LABELING FOR CHILDREN UNDER TWO YEARS recommended by FDA's Nonprescription Drugs Advisory Committee at its Sept. 18 meeting in Gaithersburg, Md. Members of the Arthritis Advisory Committee also attended. The committee met to discuss labeling directions for two product formulations: suspension liquid, which is labeled for use by children ages two to 11, and concentrated infant drops, labeled for use by children two and three years old. The meeting marked the second consideration by the advisory committee of issues relating to the proper dosing of pediatric medications. The first occurred in early 1995 ("The Tan Sheet" Jan. 16, 1995, p. 10).

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Bayer/J&J's Xarelto Approval For Stroke Prevention Sets Up Marketing Battle With Pradaxa

With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.

Topics

UsernamePublicRestriction

Register

PS071960

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel